Orphan programs

reMYND’s technology platform is amenable to address numerous other, highly debilitating protein-misfolding disorders, such as Amyotrophic Lateral Sclerosis (ALS), to discover and develop first-in-class drug candidates. Proof-of-concept in ALS is currently ongoing.